Text Size

Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases

Daull P., Baudouin C., Liang H., Feraille L., Barabino S., Garrigue J.-S.

  • 2021
  • Ocular Immunology and Inflammation
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology

    Drug Delivery

  • Categories

    Preclinical development

  • Affiliations

    Ophthalmic Innovation Center, Santen SAS, Evry, France; CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France; Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France; Iris Pharma, Les Nertières, La Gaude, France; Ocular Surface and Dry Eye Center, Ospedale L. Sacco, University of Milan, Milan, Italy

Related Publications

Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

Daull P., Nagano T., Gros E., Feraille L., Barabino S., Garrigue J.-S.

Safety and tolerability of overdosed artificial tears by abraded rabbit corneas

Daull P., Raymond E., Feraille L., Garrigue J.-S.

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022